# Scott Disick's Weight Loss Praised in 'The Kardashians' Premiere; Ozempic's Potential in Managing Kidney Disease Complications; Semaglutide Linked to Erectile Dysfunction Risk in Men



**Scott Disick's Weight Loss Praised in 'The Kardashians' Season Five Premiere**

In the season five premiere of "The Kardashians," which aired on Hulu on May 23, 2024, Kris Jenner and Khloe Kardashian commended Scott Disick for his noticeable weight loss. Jenner and Kardashian visited Disick’s home in Calabasas, California, with Jenner stating, “Wow, somebody’s lost a lot of weight. You look great.”

The transformation follows Disick's efforts towards better health after a car accident in August 2022 involving his Lamborghini, which resulted in a minor head injury. During the episode, it was revealed that Disick’s fridge contained a box of Mounjaro, a diabetes medication known for its weight loss effects. This sparked reactions from viewers on social media, questioning if it was part of a brand deal.

Disick shares three children with Kourtney Kardashian and has been on a path of health recovery since the accident. New episodes of "The Kardashians" are available on Hulu in the US and Disney+ in the UK.

**Ozempic's Potential in Reducing Kidney Disease Complications**

A recent study published in the New England Journal of Medicine suggests that weekly injections of Ozempic, a drug primarily used for managing type 2 diabetes, may significantly decrease the risk of kidney complications, heart issues, and death in patients with chronic kidney disease and diabetes. The study included around 3,500 participants from 28 countries and showed a 24% reduction in severe outcomes in those administered the drug compared to a placebo.

Ozempic’s active ingredient, semaglutide, mimics the GLP-1 hormone regulating blood sugar levels. Researchers are seeking FDA approval to extend Ozempic’s use to include the reduction of chronic kidney disease progression in diabetics.

**Semaglutide and Increased Risk of Erectile Dysfunction**

Researchers from the University of Texas have found that men who use semaglutide, present in drugs like Ozempic and Wegovy, have heightened risks of developing erectile dysfunction and testosterone deficiency. The study analyzed over 3,000 obese, non-diabetic men and observed a 3.5 times increased risk of erectile dysfunction within a month of starting treatment.

The study calls for more research, indicating a need to understand the long-term effects of semaglutide on male sexual health. Despite these concerns, the overall benefits for those at high risk of cardiovascular events or other complications of obesity may still outweigh the risks.